चिन्ह | एक्सचेंज | करेंसी |
|---|
प्रकार | 5 मिनट | 15 मिनट | प्रति घंटा | दैनिक | मासिक |
|---|---|---|---|---|---|
| मूविंग एवरेज | मजबूत खरीद | मजबूत खरीद | मजबूत खरीद | मजबूत खरीद | मजबूत खरीद |
| तकनीकी संकेतक | मजबूत खरीद | मजबूत खरीद | मजबूत खरीद | खरीदें | मजबूत खरीद |
| सारांश | मजबूत खरीद | मजबूत खरीद | मजबूत खरीद | मजबूत खरीद | मजबूत खरीद |
नाम | अंतिम | उच्च | निम्न | बदलाव | बदलाव % | वॉल्यूम | समय | ||
|---|---|---|---|---|---|---|---|---|---|
| 34.25 | 35.90 | 34.10 | -1.25 | -3.52% | 512.00 | BSE | |||
| 57.80 | 58.00 | 55.00 | +4.95 | +9.37% | 1.42M | NSE | |||
| 0.80 | 0.00 | 0.00 | 0.00 | 0.00% | 0.00 | NSE | |||
| 219.80 | 224.80 | 217.50 | -4.45 | -1.98% | 50.30M | NSE | |||
| 570.90 | 619.00 | 568.00 | -23.80 | -4.00% | 120.40K | NSE | |||
| 487.80 | 493.90 | 485.10 | -10.10 | -2.03% | 16.95M | NSE | |||
| 658.40 | 671.60 | 657.00 | -12.70 | -1.89% | 4.22M | NSE | |||
| 16.50 | 17.60 | 15.30 | -0.52 | -3.06% | 881.39K | NSE | |||
| 492.55 | 511.00 | 492.05 | -16.65 | -3.27% | 1.38M | NSE | |||
| 13.98 | 14.60 | 13.98 | 0.00 | 0.00% | 0.00 | BSE | |||
| 168.35 | 173.00 | 167.05 | -5.25 | -3.02% | 18.29M | NSE | |||
| 593.40 | 619.70 | 592.25 | -1.05 | -0.18% | 47.62K | NSE | |||
| 1.60 | 1.60 | 1.60 | 0.00 | 0.00% | 0.00 | NSE | |||
| 889.40 | 983.00 | 810.00 | +63.37 | +7.67% | 52.37M | NSE | |||
| 205.25 | 210.40 | 201.50 | -2.15 | -1.04% | 25.78K | NSE |
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.